Centrum Research’s research report on Dr. Reddys Labs
We maintain Hold rating for Dr. Reddys Labs (DRL) with TP at Rs2,200 (earlier Rs2,000) based on 21x March20E EPS of Rs104.6. DRLs Q1FY19 revenues were in line with our estimates. However, EBIDTA and net profit exceeded our expectations. The drug maker reported a 12% YoY growth in revenues, 1,090bps improvement in margin to 20.6% and a 615% YoY growth in net profit. DRL is facing pricing pressure in the US generic market due to channel consolidation and stiff competition from new players. Key positive risk to our assumptions includes faster approval of ANDAs by US FDA and key negative risk includes increase in pricing pressure in the US market. We recommend a switch to Aurobindo Pharma or Pfizer.
We maintain Hold rating for DRL with a TP of Rs2,200 based on 21x March20E EPS of Rs104.6 and with a upside of 3.1% from CMP.
For all recommendations report,click here
Disclaimer:The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions. Read More
First Published on Aug 2, 2018 06:44 pm